Background/Aims: Renal tubular epithelial-mesenchymal transition (EMT) is regarded as an important factor leading to renal interstitial fibrosis. Erythropoietin (EPO) has been reported to attenuate renal fibrosis. The mechanism underlying this protective effect of EPO remains unclear. In this study, we aim to identify possible mechanisms of the EPO renoprotective effect. 
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Introduction
Renal interstitial fibrosis is a common outcome of end stage renal disease (ESRD). Chronic hypoxia is an important pathway that leads to end-stage renal failure, and it is also important in renal fibrogenesis [1] . The development of renal interstitial fibrosis in chronic kidney disease (CKD) is aggravated by chronic tubulointerstitial hypoxia. A previous study has suggested that chronic tubulointerstitial hypoxia induced by peritubular capillary loss aggravates the development of tubulointerstitial fibrosis in remnant kidneys reaction was performed using SuperScript TM II reverse transcriptase (Invitrogen). cDNA was detected using SYBR ® Select Master Mix (Life technology, California, USA). For quantification of miRNAs, a miScript PCR Starter Kit (Qiagen, Hilden, Germany) was used, which consists of the miScript reverse transcription kit, miScript primer assays, and miScript SYBR Green PCR kit. GAPDH and U6 RNA were used as internal loading controls for mRNAs and miRNAs, respectively. After reactions, the Ct data were determined using default threshold settings, and the mean Ct was determined from the duplicate PCRs. The miR level of each sample was calculated by 2 -ΔCt , then 2 -ΔΔCt , which represented the fold change between two groups. ΔCt= Ct miR value of target gene -Ct value of internal referee U6 RNA , ΔΔCt=ΔCt treatment -ΔCt control .
Luciferase reporter assay For Ets-1 3'UTR luciferase reporter experiments, oligonucleotides harboring wild-type or mutated miR-200 binding sites from the human Ets-1 3'UTR were annealed and ligated into the EcoRI and PstI sites of the pGL3-control-mcs2 reporter vector (constructed by Wang Tao, PhD). HK-2 cells were seeded in a 48-well plate the day before transfection. HK-2 cells were cotransfected using the Ets-1 3'UTR reporter plasmid along with the pRL-TK Renilla plasmid (Promega, Madison, WI) and miR-200b mimics (50 nM) or a miRNA-negative control (50 nM). The miR-200b-200a-429 promoter firefly luciferase reporter assays were performed in a similar manner by using 100 ng miR-200b-200a-429 promoter firefly luciferase reporter plasmid [18] with 200 ng pCMV5-Smad7 plasmids (Addgene, MA, USA) or Smad7 siRNA (GenePharma). Cells were harvested 48 hours later and measured using the Dual-Luciferase assay kit (Promega).
Western blotting
Western blotting was performed on cell lysates collected from HK-2 cells for detection of α-SMA, E-cadherin and Ets-1. Proteins were separated on a Sodium dodecyl sulfate/Polyacrylamide gel electrophoresis gel (SDS/PAGE), transferred onto a polyvinylidene fluoride (PVDF) membrane and subjected to immunoblot analysis. Blotting was performed using antibodies against α-SMA (1:500, Abcam, Cambridge, MA, USA), E-cadherin (1:500, Abcam), Ets-1 (1:500, Abcam) and GAPDH (1:10000, Abcam). After rinsing with Tris-buffered saline supplemented with 0.1% Tween 20 (TBST), the membranes were incubated with a horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-goat antibody for 60 min at room temperature. The detection of specific signals was performed using enhanced chemiluminescence (ECL, Amersham Biosciences, Little Chalfont, UK).
Immunofluorescence HK-2 cells, which were grown and stimulated in six-well chamber slides, were fixed using 3.7 % formaldehyde for 10 min at 4°C. The HK-2 cells membrane was permeabilized using 0.2 % Triton X-100 for 5 min. Then the cells were incubated with an anti-α-SMA antibody overnight at 4°C. After that, cells were exposed to a goat anti-rabbit Cy3 conjugated secondary antibody for 2 h at 37℃.
Statistical Analyses
Data reported represent mean ± SEM of at least three independent experiments. Statistical significance, defined as P < 0.05, was evaluated using one-way analysis of variance with SPSS software (version 19.0).
Results

EPO Treatment Attenuated hypoxia-induced EMT in HK-2 Cells
Epithelial cells undergoing EMT acquire expression of mesenchymal markers such as α-SMA and lose expression of epithelial markers such as E-cadherin. Hypoxia was induced in vitro by incubating HK-2 cells in 1% O 2 and 5% CO 2 . After 48 h of hypoxia, HK-2 cells underwent a morphological and phenoptypic transition characteristic of EMT, which was attenuated by EPO (Fig. 1A) . The level of α-SMA was significantly increased compared with levels in normoxic cells, whereas the E-cadherin protein was decreased in hypoxic cells (P < 0.05; Fig. 1B,C) . Treatment with EPO attenuated the hypoxia-induced upregulation of α-SMA. Expression of E-cadherin was correspondingly increased in hypoxic cells after treatment with EPO. Immunofluorescence detection of α-SMA confirmed the results of the western blotting. These changes are all characteristic of myofibroblasts (Fig. 1D) . 
EPO represses hypoxia-induced EMT by upregulating miR-200b in HK-2 cells
To elucidate the underlying mechanism, the putative role of the miRNAs was investigated. miR-200 is a well-studied miRNA involved in EMT. inhibitor was used before treatment with EPO under hypoxic conditions. PCR and western blotting showed that the protective effect of EPO in attenuating EMT was eliminated by miR200b inhibition (Fig. 2C, D) . Expression of α-SMA was markedly increased and E-cadherin expression was markedly decreased by miR-200b inhibition in the EPO-treated hypoxic HK-2 cells. Immunofluorescence detection of α-SMA confirmed the results of the western activity of this construct was tested after transfection in HK-2 cells. EPO dramatically enhanced the luciferase activities of miR-200b-200a-429 promoter (Fig. 3A) . As revealed previously, Smad7 completely blocked the TGF-1-mediated miR-200 family downregulation [19] . Therefore, we hypothesized that Smad7 may is involved in EPO activated miR-200b-200a-429 transcription in HK-2 cells. To further demonstrate this, the promoter was cotransfected with Smad7 expressing plasmid into HK-2 cells. The results showed that Smad7 enhanced the activities of miR-200b-200a-429 promoter (Fig. 3B) . Furthermore, overexpression of Smad7 also increased expressions of miR-200a, miR-200b, and miR-429 compared with control (Fig. 3C) . We next investigated if EPO upregulated mir-200b-200a-429 transcription in a Smad7 dependent manner. In EPO-treated HK-2 cells, knockdown of Smad7 repressed the luciferase activity which was enhanced by EPO (Fig. 3D) . To further confirm the contribution of Smad7 in EPO-induced mir-200b-200a-429 luciferas activity, we investigated the expression of Smad7 in EPO-treated HK-2 cells. The protein levels of Smad7 increased under EPO treatment compared with control (Fig. 3E) . Taken together, these results indicate that Smad7 is an important mediator in EPO activated miR-200b-200a-429 transcription.
EPO represses hypoxia-induced EMT by decreasing Ets-1 in HK-2 cells
Ets-1 is an important transcription factor recognized as an important mediator of fibrosis [20] . Whether Ets-1 is involved in inducing EMT in HK-2 cells under hypoxic conditions found that Ets-1 expression was markedly reduced by miR-200b in HK-2 cells (Fig. 5D, E) . To clarify the interaction between miR-200b and the functional miR-200b seed regions within the 3'UTR region of Ets-1, luciferase reporter assays were performed. Transfection with miR200b resulted in a significant reduction in luciferase activity in HK-2 cells transfected with the wild-type construct of the Ets-1 3'UTR, whereas the luciferase activity of the mutanttype reporter construct remained unchanged by miR-200b mimics (Fig. 5F ).
Discussion
Chronic hypoxia is a crucial process in renal fibrogenesis. The development of renal interstitial fibrosis in CKD is aggravated by chronic tubulointerstitial hypoxia [21] . It is very important to seek new treatment strategies for these conditions. Although specific therapies that inhibit the progression of CKD are unavailable, preventing EMT would be one Cellular Physiology and Biochemistry therapeutic option to potentially inhibit renal fibrosis [22] . EPO is a glycoprotein that has a critical hormonal role in regulating erythrocyte production, and it can protect a wide variety of tissues from diverse injuries in addition to its role in erythropoiesis [23] . In this study, it has been shown that EPO attenuates hypoxia-induced EMT in HK-2 cells, and this can be mediated by upregulating miR-200 and suppressing the expression of Ets-1 (Fig. 6) . For the first time, we showed that EPO activates the transcription of mir-200 via association with Smad7. EPO has validated anti-inflammatory, -oxidant, and -apoptotic effects when it is used prior to ischemia. Most studies have focused on EPO preconditioning in kidney ischemic reperfusion injury (IRI). EPO has been shown to reduce glomerular dysfunction and tubular injury, and reduce apoptotic cell death. The anti-apoptotic effects of EPO are dependent on JAK2 signaling [24] . As a widely-used erythropoiesis-stimulating agent in CKD patients, EPO has also recently been used as an antifibrotic agent. EPO treatment protects against chronic renal injury by inhibiting stress induced senescence and EMT in unilateral ureteric obstruction (UUO) mouse model [25] . The current study has demonstrated that EPO represses hypoxia-induced EMT in HK-2 cells, and it subsequently attenuates the expression of α-SMA and restores the expression of E-cadherin. EPO treatment produced renal protective effects and inhibited TGF-β induced EMT in vivo and in vitro. Previous studies have shown that EPO is likely to counteract TGF-β induced EMT by decreasing Smad-2 phosphorylation [16] . Other studies have indicated that EPO significantly improves renal function, reduces tubular injury and prevents tubular cell apoptosis [26] .
miRNAs may play important roles in tubular epithelial cell EMT and renal fibrosis. Previous studies have shown that miR-200 family inhibit EMT through direct targeting of ZEB1 and ZEB2, which encode transcriptional repressors of E-cadherin in kidney tubular cells [27] . miR-200b could ameliorate tubulointerstitial fibrosis by inhibition of EMT of tubular epithelial cells in UUO model mice [28] . The current results demonstrate that miR200b is involved in hypoxia-induced EMT. Hypoxia down-regulates expression of miR-200a, miR-200b and miR-429 in HK-2 cells. Loss of the miR-200 family has been shown to be highly correlated with the mesenchymal phenotype. Recent findings revealed that miR-200b is down-regulated by hypoxia to induce an angiogenic response in endothelial cells [17] . Reexpression of miR-200b blocked hypoxia-induced EMT in lung cancer cells, and knocking down Notch-1 by siRNA under hypoxia resulted in up-regulated miR-200b expressions [29] . Other findings demonstrate that suppression of DICER is sufficient to reduce miR-200 levels and enables cells to undergo EMT in hypoxic human breast cancer cells [30] . miR-200 has been reported to be involved in hypoxic/ischemic events [31] . The current study has, for the first time, indicated that miR-200 mediates the protective effects of EPO in the EMT of HK-2 cells. EPO enhances the beneficial influence of mesenchymal stem cells so that they exert a better restorative effect following TGF-β induced fibrosis in HK-2 cells by upregulating the expression of miRNAs in microvesicles, including miRNA-200 [15] . However, the mechanism underlying EPO regulation of miRNAs remains unclear. The current study has demonstrated that EPO activated miR-200b-a-429 promoter dependent on upregulating Smad7, which can enhance miR-200b-a-429 promoter activity. Smad7 inhibits the fibrotic effect of TGF-β on renal tubular cells by blocking Smad2 activation which provide a therapeutic strategy for renal fibrosis [32] . However, the relationship of Smad7 and miR-200b-a-429 promoter need to be further elucidated.
Ets-1 is a member of the Ets family of transcription factors that share a unique Ets DNA binding domain. The current study has demonstrated that EPO-induced miR-200 expression attenuates EMT by repressing Ets-1 expression. There are some controversies about the role of Ets-1 in fibroblasts. Ets-1 has been reported to act as a negative regulator of COL1 production and EMT in TGF-β-stimulated renal cells [33] . Ets-1 efficiently antagonizes the profibrotic effects of TGF-β in human fibroblasts [34] . However, other studies reported that ETS-1 is a common mediator of the proinflammatory and profibrotic effects of angiotensin II (Ang II)-induced hypertensive renal damage [35] . Knockdown of Ets-1 attenuates Ang II-induced fibroblast activation [36] . Our study favors the view that Ets-1 expression has the profibrotic effect under hypoxia. In the present study, with cultures exposed to hypoxic conditions, it was found that Ets-1 was upregulated after EPO treatment. EPO can protect retinal cells by downregulating hypoxia-inducible factor-1 (HIF-1) expression in diabetic rats [37] . Oikawa reported that hypoxia induces Ets-1 via the activity of HIF-1 [38] . In the present study, it was found that miR-200b is crucial in protecting HK-2 cells from EMT via Ets-1 direct targeting under hypoxic conditions. Previous findings have revealed that hypoxia-sensitive miR-200b is involved in the induction of angiogenesis via directly targeting Ets-1 in human microvascular endothelial cells [17] . Overexpression of miR-200c results in the negative regulation of its gene targets including ZEB1, ETS1 and FLT1, which facilitate gain of epithelial characteristics that are required for mesenchymal-to-epithelial transition behavior in human colorectal cancer cells [39] . This finding suggests that miR-200 expression is increased after EPO treatment, which targets and represses Ets-1 in HK-2 cells under hypoxic conditions. EPO may attenuate EMT by regulating HIF-1 and miR-200 in human proximal tubular cells under hypoxic conditions. Further investigation is required to elucidate the underlying mechanism of the EPO induction of miR-200 upregulation.
In conclusion, these data provide evidence that miR-200 mediates the protective effects of EPO on EMT in hypoxic HK-2 cells. EPO attenuated hypoxia-induced EMT in HK-2 cells by increasing miR-200 expression. It is likely to counteract hypoxia induced EMT via repression of Ets-1. These results will help to uncover the possible mechanisms of the EPO renoprotective effect, which could be mediated by regulation of miR-200 in hypoxia-induced EMT.
